Peptigrade

Growth Hormone Axis

Tesamorelin

Tesamorelin acetate — N-[(3E)-1-oxo-3-hexen-1-yl]-GHRH(1-44), a trans-3-hexenoyl-modified 44-amino-acid human GHRH analog·Also known as: Egrifta, Egrifta SV, Egrifta WR, TH9507, Trans-3-hexenoyl-GHRH(1-44), Tesamorelin F8

FDARegulatory status

FDA-approved. Tesamorelin acetate was approved November 10, 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (NDA 022505). A supplemental BLA for Egrifta WR (the F8 weekly-reconstitution formulation) was approved March 2025, maintaining bioequivalence while cutting injection volume by more than half. Tesamorelin remains the only FDA-approved member of the GHRH-analog class.

WADARegulatory status

Prohibited at all times (S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics; specifically S2.2 GHRHs and GHRH analogs) on the 2026 WADA Prohibited List (in force January 1, 2026). FDA approval for a specific medical indication does not override WADA classification.

Regulatory note ·Egrifta (tesamorelin for injection) and Egrifta WR (F8 formulation) are the approved human drugs, marketed by Theratechnologies. The FDA-approved label restricts the indication to HIV-associated lipodystrophy with excess abdominal fat; off-label use in general body composition, cognition, aging, or athletic contexts is not covered by the approval and is not supported by controlled trials in those populations. The April 15, 2026 FDA 503A Categories Update concerns compounded bulk drug substances and does not affect the status of the approved Egrifta / Egrifta WR products. Patents on the F8 formulation extend to 2033.

§ The quick take

TL;DR · Editor’s summary

Tesamorelin is the only FDA-approved GHRH analog in the world — Egrifta was approved November 10, 2010 for HIV-associated lipodystrophy on the basis of two replicated multicenter Phase 3 randomized, double-blind, placebo-controlled trials (Falutz NEJM 2007; Falutz JAIDS 2010) that together enrolled more than 800 patients and showed a ~15.4% mean reduction in CT-measured visceral adipose tissue at 26 weeks versus placebo, with durability through 52 weeks of open-label extension. That is the evidence profile Peptigrade reserves for an A: two independent Phase 3 RCTs in the target population published in major journals, a clear regulatory endpoint, FDA agreement, and an improved F8 once-weekly-reconstitution formulation (Egrifta WR) that received a supplemental BLA approval in March 2025 and is under patent to 2033. The proximal pharmacology is also A-grade and well-characterized: Stanley 2011 (JCEM) ran a randomized crossover in healthy men with frequent overnight GH sampling and documented augmented basal and pulsatile GH secretion with an IGF-1 rise of roughly 181 ± 22 μg/L — notably, peripheral insulin-stimulated glucose uptake was preserved, which is the key point distinguishing tesamorelin from exogenous GH replacement.

Beyond the label, Stanley 2019 (Lancet HIV) showed tesamorelin reduced hepatic fat fraction versus placebo in HIV patients with NAFLD (-4.1 vs +0.9 percentage points, p<0.001), and Clemmons 2017 (JCEM) documented acceptable glycemic profile in type 2 diabetes. What the evidence does not support: no Phase 3 or adequately powered Phase 2 RCT exists in non-HIV general-population body composition, cognition, sleep, or aging — the common wellness-clinic framing of tesamorelin as a 'fat-burning peptide' for healthy adults is off-label and unstudied in that population. IGF-1 must be monitored during therapy; sustained IGF-1 elevation and population epidemiologic associations with some malignancies remain the open long-term question for any GH-axis intervention.

Not WADA-exempt — prohibited at all times under S2.2.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Tesamorelin, sorted by strength of evidence.

A

HIV-associated lipodystrophy — visceral fat reduction

Strong

Two replicated Phase 3 multicenter randomized double-blind placebo-controlled trials (Falutz 2007 NEJM, Falutz 2010 JAIDS) totaling >800 HIV patients showed ~15.4% mean reduction in CT-measured visceral adipose tissue at 26 weeks vs placebo, with durability on extension through 52 weeks. FDA approval November 2010; Egrifta WR F8 sBLA approval March 2025. Label-indication evidence.

8 studiesUpdated 2026-04-20
B

Triglycerides and atherogenic lipid profile (HIV-lipodystrophy population)

Promising

Secondary endpoint across the Phase 3 program — statistically significant reductions in serum triglycerides and total cholesterol vs placebo in Falutz 2007 and replicated in Falutz 2010. Consistent signal but secondary endpoint in the label-indication trials; effect size smaller than the VAT endpoint.

4 studiesUpdated 2026-04-20
A

IGF-1 elevation and GH pulsatility (PK/PD)

Strong

Stanley 2011 (JCEM) — randomized crossover in healthy men with frequent overnight GH sampling showed tesamorelin augments basal and pulsatile GH secretion and raises IGF-1 (~181 ± 22 μg/L) while preserving peripheral insulin-stimulated glucose uptake. Directly on-target pharmacology, peer-reviewed placebo comparator, FDA Clinical Pharmacology Review (NDA 022505) consistent.

5 studiesUpdated 2026-04-20
B

Nonalcoholic fatty liver disease (NAFLD) in HIV

Promising

Stanley 2019 (Lancet HIV) — randomized double-blind placebo-controlled trial (n=61 HIV patients with NAFLD) showed tesamorelin reduced liver fat fraction vs placebo over 12 months (-4.1 vs +0.9 percentage points; p<0.001). Single well-designed Phase 2; outside the FDA label but rigorously studied.

3 studiesUpdated 2026-04-20
B

Glycemic control / insulin sensitivity

Promising

Clemmons 2017 (JCEM) — RCT in adults with type 2 diabetes showed tesamorelin raised IGF-1 within the normal range with acceptable HbA1c and fasting glucose stability over 12 weeks. Stanley 2011 showed preserved peripheral insulin-stimulated glucose uptake in healthy men. Favorable compared with exogenous GH but requires IGF-1 monitoring in practice.

4 studiesUpdated 2026-04-20
Ins.

Cognitive function in aging / mild cognitive impairment

Insufficient

No adequately powered RCT in a non-HIV aging or MCI population using tesamorelin as the intervention is in the peer-reviewed literature as of the update date. Mechanistic rationale from GH/IGF-1 biology exists, but the on-molecule controlled evidence to support the common wellness-clinic cognition claim is absent.

0 studiesUpdated 2026-04-20
D

Body composition in non-HIV adults (general lean mass / visceral fat)

Weak

No Phase 3 trial outside HIV lipodystrophy. Mechanistic and PK/PD evidence (Stanley 2011) support on-target VAT lipolysis, but in the absence of a controlled efficacy trial in otherwise-healthy adults the rubric does not support a higher grade for this off-label claim.

1 studiesUpdated 2026-04-20

§ Why this grade

Sub-scores for this outcome.

HIV-associated lipodystrophy — visceral fat reduction

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

5 / 5

GHRH-R / Gαs / cAMP / PKA / CREB / GH1 cascade is canonical endocrinology. Trans-3-hexenoyl N-terminal DPP-IV protection is well-characterized. Preservation of pulsatile GH and intact IGF-1 feedback is documented by Stanley 2011 with frequent overnight sampling and hyperinsulinemic-euglycemic clamp. Depot-selective visceral lipolysis mechanism is supported by GH-receptor biology in adipocytes.

Human studies (count + quality)

5 / 5

Two replicated multicenter Phase 3 randomized double-blind placebo-controlled trials in the target population (Falutz 2007 NEJM, Falutz 2010 JAIDS) totaling >800 patients with CT-measured VAT as the primary endpoint. Extension data to 52 weeks. Mechanistic RCT (Stanley 2011 JCEM) and indication-adjacent RCT (Stanley 2019 Lancet HIV) from independent academic groups.

Effect vs placebo

5 / 5

~15.4% mean placebo-adjusted VAT reduction at 26 weeks on CT imaging. Replicated across two Phase 3 trials. Consistent, clinically meaningful, and verifiable on quantitative imaging. Secondary lipid endpoints also placebo-separated.

Long-term safety data

4 / 5

Phase 3 program plus open-label extension on active drug supports ~52 weeks of documented exposure; post-marketing use since 2010 adds observational data. The open question is multi-year oncologic signal under chronic IGF-1 elevation, which a registration program is not powered to resolve. Does not quite reach a 5.

Side effect profile

4 / 5

Label AEs are predominantly injection-site reactions, arthralgia, extremity pain, peripheral edema, and myalgia. Transient hyperglycemia and elevated IGF-1 are monitored on-label. No unexpected serious safety signals in the pivotal program. Theoretical long-term IGF-1 oncologic risk caps this below a clean 5.

Regulatory status

5 / 5

FDA-approved November 10, 2010 (Egrifta, NDA 022505). Egrifta WR F8 sBLA approved March 2025. Only FDA-approved GHRH analog. European regulatory status is separate and more restrictive; the A grade attaches to the specific FDA-approved indication. WADA-prohibited under S2.2 — orthogonal to the medical approval.

§ What the science says

How Tesamorelin
works.

Plain-English explanation of the molecule and its proposed mechanism, written at an 8th-grade reading level so anyone can engage with it. Every claim is linked to a primary source below.

What it is

Tesamorelin is a synthetic 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH(1-44)) with a trans-3-hexenoic acid moiety conjugated to the N-terminal tyrosine (MW ~5,135.9 Da, molecular formula C₂₂₁H₃₆₆N₇₂O₆₇S, CAS 218949-48-5). The trans-3-hexenoyl modification is the structural innovation that makes the molecule a drug rather than a research peptide: it confers resistance to dipeptidyl aminopeptidase-4 (DPP-IV) cleavage of the N-terminus, which is the dominant degradation pathway for native GHRH, and extends the subcutaneous elimination half-life from minutes (native GHRH) to roughly 26–38 minutes in HIV patients at steady state. Tesamorelin was developed by Theratechnologies (Montreal), received FDA approval as Egrifta in November 2010 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and is marketed in a lyophilized subcutaneous formulation. In March 2025 the FDA approved a supplemental BLA for Egrifta WR — the F8 formulation — which maintains bioequivalence to the original Egrifta SV product while cutting injection volume by more than 50% and allowing weekly rather than daily reconstitution. Patents on the F8 formulation extend to 2033.

How it works

  1. 01

    GHRH-R agonism at pituitary somatotrophs

    Tesamorelin binds the extracellular domain of the growth-hormone-releasing-hormone receptor (GHRH-R), a class B1 Gαs-coupled GPCR expressed predominantly on somatotrophs of the anterior pituitary. Receptor activation stimulates adenylyl cyclase, elevates intracellular cAMP, activates PKA, phosphorylates CREB, and drives transcription of the GH1 gene and calcium-dependent exocytosis of GH-containing secretory granules. Receptor affinity is comparable to native GHRH and selectivity for GHRH-R over GHS-R1a (ghrelin receptor) is preserved — tesamorelin does not meaningfully raise cortisol, prolactin, or aldosterone in the studied populations (FDA Clinical Pharmacology Review, NDA 022505, 2010).

  2. 02

    N-terminal trans-3-hexenoyl protection against DPP-IV

    The trans-3-hexenoic acid moiety on the N-terminal tyrosine blocks dipeptidyl aminopeptidase-4 (DPP-IV) cleavage, the enzymatic step that normally clips the Tyr¹-Ala² dipeptide from native GHRH and inactivates it within minutes. This is the engineering feature that makes subcutaneous dosing practical. Reported terminal half-life after SC injection in HIV patients on multiple dosing is 18.6–37.8 minutes, with Tmax ~8–10 minutes and linear dose-proportional PK across the 0.5–2 mg range (FDA Clinical Pharmacology Review; label for Egrifta / Egrifta WR, 2025).

  3. 03

    Preservation of physiologic pulsatile GH secretion

    A central mechanistic distinction of tesamorelin versus exogenous GH is that it drives endogenous somatotroph output while leaving the pulsatile architecture and IGF-1 negative-feedback loop intact. Stanley 2011 (JCEM) used 20-minute overnight GH sampling in a randomized crossover in healthy men and documented augmented basal and pulsatile GH with intact diurnal pattern; peripheral insulin-stimulated glucose uptake (measured by hyperinsulinemic-euglycemic clamp) was preserved. This is the physiology that rationalizes tesamorelin's more favorable glycemic profile compared with continuous GH replacement.

  4. 04

    IGF-1 rise and feedback-limited ceiling

    GH released from somatotrophs drives hepatic IGF-1 production. In the pivotal Phase 3 program IGF-1 rose by approximately 181 ± 22 μg/L above baseline in tesamorelin-treated patients (Falutz 2007; FDA label). Critically, IGF-1 negative feedback on the hypothalamus and pituitary is not bypassed — mean IGF-1 remained within the normal physiologic range in the trials and serves as the monitoring biomarker required by the FDA label. This feedback-ceilinged design is what prevents the tonic IGF-1 excess seen with exogenous GH.

  5. 05

    Depot-selective visceral lipolysis

    The downstream phenotypic effect most relevant to the FDA indication is selective reduction of visceral (intra-abdominal) adipose tissue with preservation of subcutaneous fat and lean mass. Proposed drivers include differential GH-receptor density and hormone-sensitive-lipase responsiveness in visceral vs subcutaneous adipocytes and enhanced fatty-acid oxidation driven by GH-induced lipolysis. Falutz 2007 (NEJM) showed ~15.4% mean VAT reduction at 26 weeks on CT imaging with preservation of subcutaneous fat and a modest increase in lean body mass — a pharmacologic profile that is qualitatively different from non-selective weight-loss interventions.

  6. 06

    Hepatic fat and NAFLD in HIV

    Stanley 2019 (Lancet HIV) extended the lipolytic mechanism to liver: in 61 HIV patients with NAFLD randomized to tesamorelin or placebo for 12 months, the tesamorelin arm showed a -4.1 vs +0.9 percentage-point change in liver fat fraction on MR spectroscopy (p<0.001) and a numerical reduction in hepatic fibrosis progression. This positions tesamorelin as a GH-axis intervention with measurable hepatic-steatosis activity in the HIV population — a meaningful extension of mechanism beyond the approved VAT endpoint.

  7. 07

    What is NOT known about the mechanism

    Whether the depot-selective visceral lipolysis and hepatic-fat effect documented in HIV-lipodystrophy and HIV-NAFLD populations generalizes to non-HIV adults with general-population obesity is unsettled — no Phase 3 exists in that population. The long-term oncologic implications of chronic feedback-ceilinged IGF-1 elevation across a broader population (given epidemiologic associations between serum IGF-1 and several malignancies) remain an open question that a ~26–52-week lipodystrophy trial is not powered to resolve. Tissue distribution of the albumin-unbound tesamorelin peptide and behavior under disease states (hepatic or renal impairment, hypoalbuminemia) are partially characterized in the FDA Clinical Pharmacology Review but remain thinner than the HIV-lipodystrophy efficacy data.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • HIV-associated lipodystrophy — reduction of excess abdominal (visceral) fat

    FDA-approved 2010 (Egrifta). Two replicated Phase 3 RCTs (Falutz 2007 NEJM, Falutz 2010 JAIDS). Egrifta WR F8 sBLA approved March 2025.

  • HIV-associated nonalcoholic fatty liver disease (NAFLD)

    Stanley 2019 Lancet HIV — 12-month randomized double-blind placebo-controlled trial in 61 HIV patients with NAFLD

  • GH pulsatility and insulin sensitivity (mechanism / PK-PD)

    Stanley 2011 JCEM — randomized crossover in healthy men with overnight GH sampling + hyperinsulinemic-euglycemic clamp

  • Type 2 diabetes — IGF-1 and glycemic safety

    Clemmons 2017 JCEM — RCT in adults with T2D evaluating IGF-1 elevation and HbA1c stability

  • Lipid profile — triglycerides and total cholesterol

    Secondary endpoints across the Phase 3 program; replicated in Falutz 2007 and Falutz 2010

  • Cardiovascular risk in people with HIV (VAT-mediated)

    Theratechnologies CROI 2025 presentations; mechanistic / exploratory, no completed Phase 3 cardiovascular-outcomes trial

  • General-population body composition (non-HIV adults)

    No Phase 3 or adequately powered Phase 2 RCT. Common off-label / wellness-clinic use is not supported by on-molecule trial evidence.

  • Cognitive function / aging / somatopause

    Mechanistic rationale only; no adequately powered RCT with tesamorelin as the intervention in a non-HIV aging or MCI population in the peer-reviewed literature as of the update date.

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    Whether the visceral-fat and hepatic-fat effects documented in HIV-lipodystrophy and HIV-NAFLD populations generalize to non-HIV adults with general-population obesity or metabolic syndrome — no Phase 3 exists in that population.

  • !

    Long-term oncologic safety under chronic dosing. Tesamorelin is FDA-label-monitored for IGF-1 elevation, and IGF-1 has epidemiologic associations with several cancers; a prospectively-powered long-duration oncologic-outcomes trial has not been completed.

  • !

    Cardiovascular outcomes (MACE) in HIV-lipodystrophy patients — mechanistic VAT reduction is robust, but whether it translates into hard cardiovascular endpoint reduction is an inference, not a demonstrated outcome in a powered trial.

  • !

    Efficacy after discontinuation. Trial extensions show durability on-drug, but VAT tends to return toward baseline after treatment is stopped, and the optimal long-term dosing schedule for maintenance has not been defined by a dedicated RCT.

  • !

    Pediatric use is not studied. The FDA label is restricted to adults; pediatric HIV-lipodystrophy PK and efficacy are not established.

  • !

    Immunogenicity over multi-year dosing — anti-drug antibody formation against the GHRH-analog backbone is plausible for any chronic peptide therapy and is not extensively characterized in the peer-reviewed literature beyond the registration studies.

  • !

    Cognitive function, sleep architecture (polysomnography endpoints), and general-adult anti-aging claims are not supported by an on-molecule controlled trial; the wellness-clinic framing outruns the evidence.

  • !

    Head-to-head comparison versus other GHRH analogs (CJC-1295, sermorelin) on VAT, body composition, or GH/IGF-1 PD has not been conducted in a controlled trial.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Tesamorelinand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • GHRH Analogs Explained: Sermorelin, Tesamorelin, and CJC-1295 With and Without DAC

    Dr. Kyle Gillett·MD, Family Medicine

    Correctly identifies tesamorelin as the only FDA-approved GHRH analog and restricts the approved indication to HIV-associated lipodystrophy. Notes that off-label use in general body composition is not supported by the same Phase 3 evidence base as the HIV indication.

    Verified credentials

  • Tesamorelin (Egrifta) — Mechanism, HIV Lipodystrophy, and Off-Label Claims

    Peter Attia MD (The Drive)·MD, Internal Medicine / Longevity

    Discusses the Falutz 2007 NEJM and Stanley 2019 Lancet HIV trials by name, acknowledges the FDA-approved indication, and is explicit that the cognition / anti-aging claims do not have an on-molecule RCT. Flags IGF-1 monitoring as a practical requirement.

    Verified credentials

  • Tesamorelin for Visceral Fat — What the Label Actually Says

    Huberman Lab·PhD Neurobiology, Stanford

    Covers the mechanism (GHRH-R agonism, preserved pulsatility, feedback-ceilinged IGF-1 rise) and the 15.4% VAT reduction number accurately. Appropriately separates the HIV-lipodystrophy indication from speculative general-population claims.

    Verified credentials

  • Tesamorelin Melted My Belly Fat — 8-Week Results (No Diet)

    Anonymous fitness influencer·Unverified

    Anecdotal before/after with no CT imaging, no controlled comparator, and extrapolation of the HIV-lipodystrophy indication to general-population body composition. Common pattern in the wellness-clinic / influencer layer. Do not weight against Falutz 2007 / Falutz 2010.

    Caution — anecdotal

§ Citations

Every claim,
linked to source.

All 14 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Metabolic effects of a growth hormone-releasing factor in patients with HIV

    Falutz J, Allas S, Blot K, et al. · N Engl J Med · 2007

    RCTPMID 17301299
  2. [02]

    Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

    Falutz J, Mamputu JC, Potvin D, et al. · AIDS · 2010

    RCTPMID 20154587
  3. [03]

    Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men

    Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK · J Clin Endocrinol Metab · 2011

    RCTPMID 21325459
  4. [04]

    Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

    Stanley TL, Fourman LT, Feldpausch MN, et al. · Lancet HIV · 2019

    RCTPMID 31296487
  5. [05]

    Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes

    Clemmons DR, Miller S, Mamputu JC · J Clin Endocrinol Metab / PLoS One · 2017

    RCTPMID 28324062
  6. [06]

    Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

    Sivakumar T, Mechanick JI, Fonseca V · Drugs · 2011

    Systematic reviewPMID 21668043
  7. [07]

    Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

    Stanley TL, Grinspoon SK · HIV AIDS (Auckl) · 2011

    Systematic reviewDOI
  8. [08]

    Tesamorelin: a hope for ART-induced lipodystrophy

    Dhillon S · J Pharmacol Pharmacother · 2011

    Systematic reviewDOI
  9. [09]

    Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCBI Bookshelf · 2020

    Systematic reviewLink
  10. [10]

    EGRIFTA WR (tesamorelin for injection) prescribing information — FDA label, 2025 revision (NDA 022505 s020)

    U.S. Food and Drug Administration / Theratechnologies · FDA · 2025

    RegulatoryLink
  11. [11]

    Clinical Pharmacology and Biopharmaceutics Review — Tesamorelin (NDA 022505, 2010)

    U.S. Food and Drug Administration, Center for Drug Evaluation and Research · FDA · 2010

    RegulatoryLink
  12. [12]

    FDA approval of Egrifta WR (tesamorelin F8 formulation) sBLA — March 2025

    Theratechnologies / Contagion Live · Contagion Live · 2025

    RegulatoryLink
  13. [13]

    WADA 2026 Prohibited List (in force January 1, 2026) — Section S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2.2 GHRH analogs)

    World Anti-Doping Agency · WADA · 2026

    RegulatoryLink
  14. [14]

    Tesamorelin — molecular profile, trans-3-hexenoyl modification, Theratechnologies development history, Egrifta / Egrifta SV / Egrifta WR formulations

    Wikipedia contributors · Wikipedia · 2026

    Systematic reviewLink

§ Adjacent peptides

Worth reading
alongside this.

Compare

CJC-1295

The long-acting DAC-albumin GHRH analog that was being developed for the same HIV-lipodystrophy indication tesamorelin won. ConjuChem's Phase 2 program was terminated 2008; tesamorelin reached FDA approval in 2010. Useful comparator for what a fully developed GHRH analog looks like versus a halted one.

Read its grades

Compare

Sermorelin

The short-acting GHRH(1-29) parent backbone. Same receptor (GHRH-R), similar preservation of pulsatile GH, but a very different evidence base — sermorelin's human trial program is thinner and no member of the class other than tesamorelin is FDA-approved.

Read its grades

Compare

Ipamorelin

Complementary mechanism at GHS-R1a rather than GHRH-R. Often compared with or stacked against GHRH analogs in off-label practice. Its safety and PK/PD profile is distinct from tesamorelin's and should not be extrapolated in either direction.

Read its grades

Compare

IGF-1 (LR3)

The direct downstream effector that tesamorelin elevates endogenously and feedback-ceilings. Users considering exogenous IGF-1 should compare with tesamorelin's feedback-intact profile — the two interventions have very different safety signatures despite acting on the same axis.

Read its grades

Compare

Retatrutide

A different mechanistic approach to visceral adiposity (GLP-1 / GIP / glucagon triagonist) in a different population. Relevant comparator for anyone framing tesamorelin as a general-population visceral-fat drug — retatrutide has the Phase 2/3 program tesamorelin does not have outside HIV lipodystrophy.

Read its grades

Where to research further

Looking for Tesamorelin
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →